Single Surgical Centre Experience with Transcatheter Mitral Valve Therapies
Rashmi Yadav, Alison Duncan, Cesare Quarto, Ulrich Rosendahl, Simon Davies, Neil Moat.
Royal Brompton Hospital, London, United Kingdom.
OBJECTIVE: In our cardiac surgical practice of complex mitral valve patients, we are faced with a small cohort of prohibitively high-risk patients. We have treated these patients with catheter-based interventions using a heart-team approach led by cardiac surgeons. Broadly, two generic types of devices have been used for mitral valve pathologies; devices designed specifically for the mitral valve or those devised originally for the aortic position but adapted to the mitral. Our experience with these therapies include first-in-man transapical mitral valve implants (TMVI) of an apically tethered device (Tendyne) and transcatheter valve implant of aortic prostheses (Edwards Sapien and Direct Flow) in the mitral position. We report our initial experience.
METHODS: Between March2013 and December2015, a total of 13 patients were treated with novel TCV therapies. Of these, 4 patients had native mitral valve disease and underwent TMVI with the Tendyne prosthesis. A further 9 patients had undergone previous mitral valve surgery of whom 4 had failing mitral bioprostheses and 5 had recurrent MR following mitral repair. All patients had MR grade 4 and severe pulmonary hypertension. In this group, Valve in Valve (ViV) or Valve in Ring (ViR) implantation was carried out in 6 patients with the Edwards Sapien system, two with Direct Flow and one with Tendyne TMVI.
RESULTS: Device success was achieved in all patients. There were no procedural complications, no valve malpositioning or embolization and no access site complications. No patient had residual significant MR or significant mitral gradient. There was no 30 day mortality or CVA. All patients were discharged to their own home. At 6 month follow up, all (N=7) patients were alive and with significant improvement of their functional capacity.
CONCLUSIONS: An armamentarium of TCV options is required in surgical centres to be able to treat the full range of mitral valve pathologies. In our experience, a high risk group of patients can be treated successfully with low morbidity and mortality using these novel therapies.
|Age at Intervention||MV pathology||Previous Surgery||Type of Device||Device Size|
|77||MR||MVR, 31mm Carpentier-Edwards||Sapien XT||29|
|68||MR||MVR, 29mm Carpentier-Edwards||Sapien XT||29|
|84||MR||MVR, 29mm Medtronic Mosaic||Sapien XT||26|
|52||MS+MR||MV Repair, 32mm CE Physio Ring,||Sapien XT||29|
|83||MR+MS||MVR, 27mm Aspire||Sapien XT||26|
|33||MS+MR||MV Repair, 26mm CE Physio Ring||Sapien XT||23|
|66||MR||MV Repair, 28mm McCarthy Adams,||Direct Flow||23|
|71||MR||MV Repair, 34mm CE Physio Ring,||Direct Flow||27|
|74||MR||MV Repair, 38 mm CE Physio Ring||Tendyne||32.5x34.5|
Back to 2016 Annual Meeting Cardiac Track